Cesca Therapeutics And ThermoGenesis Announce Major Global Distribution Agreement For The Company’s X-Series® Products

RANCHO CORDOVA, Calif., Sept. 9, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary (the “Company”), filed a Form 8-K last Friday with the Securities and Exchange Commission announcing the signing of an exclusive, global … Continued

Cesca Therapeutics To Present At The H.C. Wainwright 21st Annual Global Investment Conference

RANCHO CORDOVA, Calif., Sept. 3, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Jeff Cauble, Vice President of Finance and Principal Accounting Officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10 at 12:30 … Continued

Cesca Therapeutics Announces Improved Second Quarter 2019 Financial Results and Provides Corporate Update

Revenue Grows by 115% and the Company Records Positive Adjusted EBITDA  for the Second Quarter of 2019 Conference Call to be Held Today at 1:30 p.m. PDT/4:30 p.m. EDT RANCHO CORDOVA, Calif., Aug. 13, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, … Continued

Cesca Therapeutics To Announce Financial Results For The Second Quarter Ended June 30, 2019 And Host A Conference Call On August 13

RANCHO CORDOVA, Calif., Aug. 6, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that the Company will release its financial results for the second quarter ended June 30, 2019 on Tuesday, August 13, 2019 after the close of trading.  A conference call … Continued

America’s Largest Cord Blood Bank, CBR®, Upgrading to ThermoGenesis’ AXP® II System

RANCHO CORDOVA, Calif., July 23, 2019 /PRNewswire/ — ThermoGenesis, a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL) and a market leader in automated cellular processing, today announced that CBR® (Cord Blood Registry), the country’s largest newborn stem cell storage bank has begun the process to transition to ThermoGenesis’ next-generation AXP® II System for the rapid … Continued

Cesca Therapeutics Regains Nasdaq Listing Compliance

RANCHO CORDOVA, Calif., June 26, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that on June 25, 2019 the Company received notification from the Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that it has regained compliance with Nasdaq Listing … Continued

Cordlife to Use the ThermoGenesis AXP® II System for Rapid Processing of Cord Blood Units in India

RANCHO CORDOVA, Calif., June 25, 2019 /PRNewswire/ — ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing, today announced that it has entered into a strategic agreement with Cordlife Group Limited (“Cordlife Group”) to provide its proprietary, next-generation AXP® II System, for the rapid processing of cord … Continued

ThermoGenesis Receives Health Canada Approval of its Next-Generation AXP® II System for Cord Blood Processing

Marks Second Product Approval from Health Canada This Year RANCHO CORDOVA, Calif., June 18, 2019 /PRNewswire/ — ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing, today announced that it has received Health Canada approval of its next-generation AXP®II system for cord blood processing. The AXP® II, together with the … Continued

ThermoGenesis to Participate in The Orthobiologic Institute’s 10th Annual PRP & Regenerative Medicine Symposium

Company to promote its PXP® cellular processing system RANCHO CORDOVA, Calif., June 5, 2019 /PRNewswire/ — ThermoGenesis Corp., a wholly owned subsidiary of Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing, today announced that it will participate in and exhibit its novel PXP® System, for point-of-care preparation of bone marrow concentrate … Continued

Cesca Therapeutics Announces 1-for-10 Reverse Split Of Common Stock

Trading on a Post-Split Basis is Scheduled to Begin on June 5, 2019 RANCHO CORDOVA, Calif., June 4, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that it has amended its Sixth Amended and Restated Certificate of Incorporation to reflect … Continued

© 2019 ThermoGenesis Corp.
How may we help?